New combo attack aims to wipe out lingering leukemia cells
NCT ID NCT03128879
Summary
This study is testing if adding a drug called venetoclax to a patient's current ibrutinib or acalabrutinib treatment can help eliminate more cancer cells. It is for adults with high-risk chronic lymphocytic leukemia (CLL) who have been on one of those drugs for at least a year but still have detectable cancer. The main goal is to see if the combination can make the cancer undetectable in the bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.